Globus Medical to acquire Nevro for $5.85 per share
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies,
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid ...
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback